Huntington's disease: molecular basis of neurodegeneration
暂无分享,去创建一个
[1] M. Hayden,et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.
[2] H. Paulson,et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.
[3] S. Tabrizi,et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.
[4] K. Sakamaki,et al. Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation. , 2002, Human molecular genetics.
[5] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[6] P. Patterson,et al. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] L Gan,et al. HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2* , 2001, The Journal of Biological Chemistry.
[8] Kiyoshi Inoue,et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. , 2002, Genes & development.
[9] K. Dewhurst,et al. Socio-Psychiatric Consequences of Huntington's Disease , 1970, British Journal of Psychiatry.
[10] S. Folstein,et al. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease , 1987, Brain Research.
[11] Paul R. Sanberg,et al. 3-Nitropropionic acid animal model and Huntington' s disease , 1997, Neuroscience & Biobehavioral Reviews.
[12] D. Rubinsztein,et al. Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease , 2001, Journal of medical genetics.
[13] P. Mecocci,et al. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex , 1999, Neuroscience Letters.
[14] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[15] Y. Agid,et al. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy , 1991, Neurology.
[16] Michael S. Levine,et al. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.
[17] M. Mcdermott,et al. A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[18] J. M. Boutell,et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.
[19] Ronald Wetzel,et al. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] L. Raymond,et al. Influence of lamotrigine on progression of early Huntington disease , 1999, Neurology.
[21] G L Johnson,et al. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation , 1993, Molecular and cellular biology.
[22] D. Rubinsztein,et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] H. Lehrach,et al. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. , 2001, Human molecular genetics.
[24] M. DiFiglia,et al. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease , 1995, Neuroscience.
[25] A. Hackam,et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates , 1998, Nature Genetics.
[26] M. Beal,et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[27] Junying Yuan,et al. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders , 2003, Nature.
[28] S. Folstein,et al. Clinical correlates of dementia and disability in Huntington's disease. , 1984, Journal of clinical neuropsychology.
[29] D. Housman,et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] A. Dale,et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.
[31] Leslie M Thompson,et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Penney,et al. NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.
[33] M. Dragunow,et al. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum , 1998, Neuroscience.
[34] Dale E. Bredesen,et al. Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract* , 1998, The Journal of Biological Chemistry.
[35] D. Housman,et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. MacDonald,et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.
[37] D. Rubinsztein,et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. , 2002, Human molecular genetics.
[38] A. Hackam,et al. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi , 2002, Nature Cell Biology.
[39] R. Myers,et al. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. , 1999, Human molecular genetics.
[40] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[41] A. Hackam,et al. Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.
[42] S. Benzer,et al. Genetic suppression of polyglutamine toxicity in Drosophila. , 2000, Science.
[43] D. Rubinsztein,et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.
[44] S. W. Davies,et al. Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.
[45] Rainer Duden,et al. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. , 2002, Human molecular genetics.
[46] Alison L. Barth,et al. Upregulation of cAMP Response Element-Mediated Gene Expression during Experience-Dependent Plasticity in Adult Neocortex , 2000, The Journal of Neuroscience.
[47] D. Rigamonti,et al. Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing* , 2001, The Journal of Biological Chemistry.
[48] Jacqueline K. White,et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion , 1997, Nature Genetics.
[49] S. Hersch,et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.
[50] A. Ludolph,et al. 3-Nitropropionic Acid - Exogenous Animal Neurotoxin and Possible Human Striatal Toxin , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[51] A. Novelli,et al. Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.
[52] A. Mantovani,et al. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. , 1992, The Journal of biological chemistry.
[53] He Li,et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity , 2000, Nature Genetics.
[54] K. Fischbeck,et al. Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.
[55] Richard I. Morimoto,et al. Polyglutamine protein aggregates are dynamic , 2002, Nature Cell Biology.
[56] I. Kanazawa,et al. In situ nick end-labeling detects necrosis of hippocampal pyramidal cells induced by kainic acid , 1996, Neuroscience Letters.
[57] M. Goedert. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[58] Huda Y. Zoghbi,et al. Amino acids in a region of ataxin-1 outside of the polyglutamine tract influence the course of disease in SCA1 transgenic mice , 2002, NeuroMolecular Medicine.
[59] H. Zoghbi,et al. Identification of genes that modify ataxin-1-induced neurodegeneration , 2000, Nature.
[60] H. Zoghbi,et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. , 2001, Human molecular genetics.
[61] F. Hartl,et al. The role of molecular chaperones in protein folding , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] G Norbury,et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[63] Dimitri Krainc,et al. Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.
[64] I. Kanazawa,et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription , 2000, Nature Genetics.
[65] H. Lehrach,et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] T. Deacon,et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] K. Kieburtz,et al. Assessment of coenzyme q10 tolerability in huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[68] S. Folstein,et al. The association of affective disorder with Huntington's Disease in a case series and in families , 1983, Psychological Medicine.
[69] R. Dyer,et al. Mutant protein in Huntington disease is resistant to proteolysis in affected brain , 2001, Nature Genetics.
[70] T. Bolwig,et al. A Study of Psychiatric Morbidity in Patients with Huntington's Disease, Their Relatives, and Controls , 1993, British Journal of Psychiatry.
[71] D. Steindler,et al. DNA End Labeling (TUNEL) in Huntington's Disease and Other Neuropathological Conditions , 1995, Experimental Neurology.
[72] A. Fersht,et al. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[73] Harry T Orr,et al. Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in SCA1 Mice , 1999, Neuron.
[74] K. Fischbeck,et al. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. , 1998, Human molecular genetics.
[75] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[76] S. Plumb,et al. A controlled clinical trial of baclofen as protective therapy in early huntington's disease , 1989, Annals of neurology.
[77] A. Joyner,et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.
[78] David G. Drubin,et al. The actin-binding protein Hip1R associates with clathrin during early stages of endocytosis and promotes clathrin assembly in vitro , 2001, The Journal of cell biology.
[79] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[80] S. W. Davies,et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[81] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[82] D. Housman,et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila , 2002, Nature Genetics.
[83] P S Harper,et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. , 1996, American journal of human genetics.
[84] D. Rubinsztein,et al. Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.
[85] J. Penney,et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.
[86] Anne-Catherine Bachoud-Lévi,et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation , 2000, The Lancet.
[87] S. Folstein,et al. Trial of d-α-tocopherol in Huntington's disease , 1995 .
[88] Sawsan Youssef,et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.
[89] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[90] J. Penney,et al. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.
[91] D. Swaab,et al. Somatostatin 1–12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients , 1996, Brain Research.
[92] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[93] J. Hodgson,et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.
[94] Y. Liu. Expression of Polyglutamine-expanded Huntingtin Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line* , 1998, The Journal of Biological Chemistry.
[95] R. Durbin,et al. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat , 1994, Somatic cell and molecular genetics.
[96] James R. Burke,et al. Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening* , 2000, The Journal of Biological Chemistry.
[97] Blair R. Leavitt,et al. Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.
[98] D. Rubinsztein. Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.
[99] Haibin Xia,et al. Allele-specific silencing of dominant disease genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[100] B. Rosen,et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.
[101] Ira Shoulson,et al. Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals , 1990, Movement disorders : official journal of the Movement Disorder Society.
[102] M. MacDonald,et al. Evidence for the GluR6 gene associated with younger onset age of Huntington’s disease , 1999, Neurology.
[103] S B Dunnett,et al. Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.
[104] S. Folstein,et al. Huntington disease in Maryland: clinical aspects of racial variation. , 1987, American journal of human genetics.
[105] K. Fischbeck,et al. CREB-binding protein sequestration by expanded polyglutamine. , 2000, Human molecular genetics.
[106] Y. Chernoff,et al. Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1 , 2002, The Journal of cell biology.
[107] S. Folstein,et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.
[108] Paolo Guidetti,et al. Early Degenerative Changes in Transgenic Mice Expressing Mutant Huntingtin Involve Dendritic Abnormalities but No Impairment of Mitochondrial Energy Production , 2001, Experimental Neurology.
[109] C A Ross,et al. Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.
[110] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[111] J. Blenis,et al. Caspase-8 Is Required for Cell Death Induced by Expanded Polyglutamine Repeats , 1999, Neuron.
[112] J L Bradshaw,et al. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[113] C A Ross,et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.
[114] H. Paulson,et al. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. , 1999, Human molecular genetics.
[115] M. Hayden,et al. Familial influence on age of onset among siblings with Huntington disease. , 2001, American journal of medical genetics.
[116] Richard J Smeyne,et al. Continuous c-fos expression precedes programmed cell death in vivo , 1993, Nature.
[117] P. Mcgeer,et al. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract , 1978, Brain Research.
[118] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[119] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[120] M. Chesselet,et al. Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum , 2001, The Journal of Neuroscience.
[121] Michael R. Hayden,et al. Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.
[122] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[123] C. Portera-Cailliau,et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[124] D. Rubinsztein,et al. Functional analysis of the Huntington's disease (HD) gene promoter. , 1998, Human molecular genetics.
[125] Blair R. Leavitt,et al. Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.
[126] D. Housman,et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.
[127] G. Bruyn,et al. Juvenile Huntington disease , 1986, Human Genetics.
[128] N. Nukina,et al. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. , 2000, Human molecular genetics.
[129] S. Tsuji,et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch , 1998, Nature Genetics.
[130] Fabrice P Cordelières,et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.
[131] F. He,et al. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid) , 1995, Neurology.
[132] S. Augood,et al. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellularin situ hybridization study , 1996, Neuroscience.
[133] L. Eckhart,et al. Human caspase 12 has acquired deleterious mutations. , 2002, Biochemical and biophysical research communications.
[134] N. Weigel,et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. , 1999, Human molecular genetics.
[135] J. Nevins,et al. Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.
[136] D. Rubinsztein,et al. The molecular biology of Huntington's disease , 2001, Psychological Medicine.
[137] Max F. Perutz,et al. Glutamine repeats and neurodegenerative diseases: molecular aspects. , 1999, Trends in biochemical sciences.
[138] J. Penney,et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.
[139] Harry T Orr,et al. Ataxin-1 Nuclear Localization and Aggregation Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice , 1998, Cell.
[140] He Li,et al. Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.
[141] K. Lindenberg,et al. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.
[142] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[143] Virginia E. Papaioannou,et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue , 1995, Nature Genetics.
[144] M. Beal,et al. Novel therapies in the search for a cure for Huntington's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[145] R. Albin,et al. Ectopically Expressed CAG Repeats Cause Intranuclear Inclusions and a Progressive Late Onset Neurological Phenotype in the Mouse , 1997, Cell.
[146] A. Hackam,et al. Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells* , 2000, The Journal of Biological Chemistry.
[147] Christopher A. Ross,et al. Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.
[148] Ole A. Andreassen,et al. Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.
[149] Shihua Li,et al. Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.
[150] M. Dragunow,et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes , 1995, Neuroreport.
[151] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[152] S. Folstein,et al. A controlled trial of idebenone in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[153] Steven Finkbeiner,et al. Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.
[154] N. Thornberry,et al. Caspases: killer proteases. , 1997, Trends in biochemical sciences.
[155] A H Schapira,et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse , 2000, Annals of neurology.
[156] R. Wetzel,et al. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human molecular genetics.
[157] L. Ellerby,et al. Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.